Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 3/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618363 | 1.00 | CASP7 (0.50) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL434862 | 0.92 | TYMS (0.51) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL21772243 | 0.89 | MEN1 (0.49) | CASP7CASP1HSD17B10TYMSHSD17B1 | |
| SCHEMBL23051659 | 0.83 | PBRM1 (0.47) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL31591224 | 0.83 | PBRM1 (0.47) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL460543 | 0.83 | CASP1 (0.57) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL1025098 | 0.80 | HSD17B10 (0.50) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL15180109 | 0.76 | HSD17B10 (0.50) | CASP7CASP1HSD17B10TYMSPBRM1 | |
| SCHEMBL7888335 | 0.76 | CASP1 (0.50) | CASP7CASP1HSD17B10PBRM1HSD17B1 | |
| SCHEMBL6206980 | 0.76 | CASP1 (0.50) | CASP7CASP1HSD17B10TYMSPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | claimed |
| JP-4762551-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | claimed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | claimed |
| WO-2023114819-A1 | TETRALINE, PHENYLCYCLOBUTANE, AND PHENYLCYCLOPENTANE ANALOGS AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114591293-A | Fused ring compound as Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109956928-B | Pyridine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-109071498-B | Kinase inhibitor and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-110655503-A | Substituted triazole compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2219448-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | Myriad Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | CASP7 884/4885CASP1 1528/4885HSD17B10 106/4885 |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | CASP7 1175/4885CASP1 1454/4885HSD17B10 988/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | CASP7 3780/4885CASP1 4432/4885HSD17B10 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.